BioCentury | Sep 6, 2019
Preclinical News

Neon improves predictions for CD4-stimulating tumor antigens

In the latest step toward breaking the barrier to identifying neoantigens displayed on MHCII, Neon has generated a systems biology model that outperforms publicly available predictors. The development brings immuno-oncology closer to personalized therapies directing...
BioCentury | Feb 1, 2019
Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
BioCentury | Jan 24, 2018
Emerging Company Profile

D over L for diabetes

...ImmunoMolecular Therapeutics LLC’s small molecule inhibitor of an HLA-DQ8 peptide could treat Type I diabetes without...
...of other disease-modifying therapies in development. About 60% of Type I diabetes patients carry the HLA-DQ8...
...de León, Staff Writer IMT-002 VBY-129 ImmunoMolecular Therapeutics LLC Virobay Inc. Cathepsin S (CTSS) Major histocompatibility complex class II DQ2 (HLA-DQ2) Major histocompatibility complex class II DQ8 (HLA-DQ8) Diabetes Celiac...
BioCentury | Nov 10, 2017
Company News

IM Therapeutics launches with T1D candidate

...to immune cells, initiating an autoimmune response. The co-founders' research suggested that blocking the major histocompatibility complex class II DQ8 (HLA-DQ8...
...The researchers identified a small molecule approved to treat hypertension, methyldopa, that bound to the HLA-DQ8...
...of Colorado School of Medicine, Aurora, Colo. Business: Endocrine/Metabolic Mary Romeo JDRF University of Colorado HLA-DQ2 Human leukocyte antigen (HLA) Major histocompatibility complex class II DQ8 (HLA-DQ8...
BioCentury | Nov 9, 2017
Company News

IM Therapeutics emerges from stealth with small molecule for T1D

...to immune cells, initiating an autoimmune response. The co-founders' research suggested that blocking the major histocompatibility complex class II DQ8 (HLA-DQ8...
...The researchers identified a small molecule approved to treat hypertension, methyldopa, that bound to the HLA-DQ8...
...disease, for which HLA-DQ2 has been identified as an immune recognition gene. Mary Romeo University of Colorado HLA-DQ2 Major histocompatibility complex class II DQ8 (HLA-DQ8) ImmunoMolecular...
BioCentury | Feb 19, 2015
Product R&D

Banking on stem cells

While stem cell developers wrestle with fine-tuning cell types, improving protocols and calling for better regulatory guidelines, few in the field are addressing one of the looming problems likely to hit once more products reach...
BioCentury | Mar 6, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...antibody controls. Ongoing work includes modifying the antibody for binding to human insulin and major histocompatibility complex class II DQ8 (HLA-DQ8...
BioCentury | Jan 23, 2014
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Orexin (hypocretin; HCRT)-based immunoassays to diagnose narcolepsy Immunoassays to determine T cell reactivity to two HCRT epitopes could be used to diagnose narcolepsy. Narcolepsy...
BioCentury | Mar 26, 2012
Emerging Company Profile

ImmusanT: Having their cake

ImmusanT Inc. is developing what could be the first treatment for celiac disease that allows patients to eat a normal diet. The company's Nexvax2 vaccine seeks to reprogram CD4+ T cells to induce gluten tolerance....
BioCentury | Dec 19, 2011
Finance

Bread for celiac vaccine

Bread for celiac vaccine ImmusanT Inc. is working on a peptide-based therapeutic vaccine designed to address the underlying problem in celiac disease, and received $20 million in series A money last week to pursue proof-of-concept...
Items per page:
1 - 10 of 22